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Abstract
Background: We conducted the current systemic review to provide up-to-date
literature summary and optimal evidence-based recommendations for ipsilateral radiation for squamous cell carcinoma of the tonsil.
Methods: We performed literature search of peer-reviewed journals through
PubMed. The search strategy and subject-specific keywords were developed
based on the expert panel's consensus. Articles published from January 2000 to
May 2020 with full text available on PubMed and restricted to the English language and human subjects were included. Several prespecified search terms
were used to identify relevant publications and additional evidence published
since the initial American College of Radiology Appropriateness Criteria

Members of the ARS Appropriate Use Criteria Steering Committee seek and encourage collaboration with other organizations on the development of
the Criteria through representation on expert panels. Participation by representatives from collaborating organizations on the expert panel does not
necessarily imply individual or society endorsement of the final document. Reprint requests to: auc@americanradiumsociety.org
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Ipsilateral Tonsil Radiation recommendation was finalized in 2012. The full
bibliographies of identified articles were reviewed and irrelevant studies were
removed.
Results: The initial search and review returned 46 citations. The authors
added three citations from bibliographies, websites, or books not found in the literature search. Of the 49 citations, 30 citations were retained for further detailed
review, and 14 of them were added to the evidence table. Articles were removed
from the bibliography if they were not relevant or generalizable to the topic, or
focused on unknown primary disease. Several commonly encountered clinical
case variants were created and panelists anonymously rated each treatment recommendation. The results were reviewed and disagreements discussed.
Conclusions: The panel provided updated evidence and recommendations for
ipsilateral radiation for squamous cell carcinoma of the tonsil in the setting of
primary radiation-based therapy and postoperative adjuvant radiotherapy. This
committee did not reach agreements for some case variants due to a lack of
strong evidence supporting specific treatment decisions, indicating a further
need for research in these topics.
KEYWORDS
ipsilateral, radiation, radiotherapy, tonsil, unilateral

1 | INTRODUCTION

2 | P A T I E N T S A N D ME T H O D S

In 2012, the American College of Radiology (ACR) published the Appropriateness Criteria for Ipsilateral Radiation for squamous cell carcinoma (SCC) of the tonsil.1 In
the interim, tonsil cancer incidence has increased, consistent with predicted epidemiologic trends, and an extraordinarily high long-term survival rate for human
papilloma virus (HPV)-related oropharynx cancer has
been reported.2-6
Favorable oropharynx cancer survival rates led to
increasing appreciation of toxicities associated with therapy. One way to potentially address toxicity is to limit
bilateral neck therapy unless truly necessary. This manuscript serves as an update to the ACR Appropriateness
Criteria and the recommendations herein should supersede those of the previous effort.
Committee note: The literature review performed for
this guideline did not return any titles that used the
American Joint Committee on Cancer (AJCC) Eighth
Edition TNM Staging System. Therefore, this review uses
descriptions of the nodes involved, rather than N categories, which entail aggregation. Multiple involved nodes
≤6 cm are common in these reports. Detailed literature
search criteria are included in Appendix S1, where articles published up to May 2020 with full English text
available on PubMed and restricted to human subjects
were presented.

2.1 | Study selection
For detailed methodology and study selection, refer to
the Appendix S1. Briefly, a search of the medical literature from peer-reviewed journals was conducted through
PubMed. The search strategy and subject-specific keywords were developed based on the expert panel's consensus. Articles published since January 2000 to May
2020 with full text available on PubMed and restricted to
the English language and human subjects were included.
The following subject-specific keywords were used:
(Tonsil/Palatine tonsil, Glossotonsillar sulcus, GTS, GT
sulcus, Tonsillar, Glossopharyngeal sulcus) AND
(Unilateral, Ipsilateral) AND (Squamous) AND (Cancer,
Carcinoma, Malignancy) AND (Radiotherapy, Radiation,
Radiation therapy, EBRT, Surgery, Transoral, TORS,
Tonsillectomy, Radical, Intensity-modulated radiation
therapy, Intensity-modulated radiotherapy, IMRT, Proton). The most recent search was performed in May 2020
to identify any additional evidence published since the
ACR Appropriateness Criteria Ipsilateral Tonsil Radiation recommendation was finalized in 2012.
The full bibliographies of identified articles were
reviewed to exclude studies which were not relevant. Of
the 46 citations returned from initial review, the authors
added 3 citations from bibliographies, websites, or books
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TABLE 1
Reference

3

Evidence table ARS Appropriate Use Criteria ipsilateral radiation for squamous cell carcinoma of the tonsil

Study type

Study population

Results

Contralateral neck failure
(CNF) and salvage therapy

Level of
evidence

Definitive (chemo)radiation
Al-Mamgani
et al9

Singleinstitution
case series

185 patients
Ipsilateral RT criteria:
T1-3N0-2b
tumors confined to the
tonsillar fossa, the soft
palate with at least 1 cm
from the midline or the
lateral pharyngeal wall
Staging imaging:
CT and/or MRI
PET/CT if needed

Median follow up: 4.1 y
Contralaleral neck failure
rates: 2/185 (1.1%)
N0: 1/92 (11 mo post RT)
N1: 0/43
N2a: 0/18
N2b: 1/32 (3 mo post RT)
5-y LC rates:
90%
5-y RC rates:
96%
5-y DFS rates:
84%

Patient #1: initial T1N2b,
salvage ND + brachytherapy
boost; NED
Patient #2: initial T2N0,
salvage ND + RT; NED

2

Lynch et al10

Singleinstitution
case series

136 patients
Ipsilateral RT criteria:
T1-3N0-2b
No tumor in tongue base or
middle and medial 1/3 of
the soft palate
Staging imaging:
CT and/or MRI
57% of patients underwent an
ipsilateral neck dissection
pre-radiotherapy

Median follow-up: 4.2 y
rates: 8/136 (5.9%)
N0: 1/28
N1: 1/20
N2a: 0/31
N2b: 6/55
N3: 0/2

Patient #1: T3N0, initial
tonsillectomy + RT alone;
not salvageable due to tonsil
recurrence and CNF. DOD.
Patient #2: T2N1, initial
tonsillectomy + ND + CRT;
failed in contralateral tonsil
and neck. Salvaged ND
+RT; NED
Patient #3: T2N2b, initial
tonsillectomy + RT alone;
salvage ND + RT; NED
Patients #4-8: T2N2b, initial
tonsillectomy + ND + CRT;
salvage ND + RT; NED

2

Huang et al11

Singleinstitution
case series

102 patients (96 with p16 stain;
62 p16+)
Ipsilateral RT criteria:
T1-2N0-2b
≤1/3 of “hemistructure” of
BOT or soft palate with
≤1 cm superficial mucosa of
“hemistructure” extension.
No muscle involvement or
deeper penetration
Staging imaging:
CT
MRI if BOT invasion
PET/CT not routinely used

Median follow up: 6 y
CNF rates: 2/96 (2.1%)
N0: 0/52
N1: 2/25
N2a: 0/11
N2b: 0/8
5-y LC rates:
p16+: 95%
p16−: 90%
5-year RC rates:
p16+: 98%
p16−: 94%

Both CNF had T2N1 disease
and received RT alone
60Gy/25 fractions with
homolateral wedge pairs.
Patient #1 (HPV+): salvage
ND; NED 12 y later
Patient #2 (HPV-): salvage
ND + RT; NED for 8 y

2

Liu et al12

Singleinstitution
case series

58 patients (9 p16+, 6 p16−,
rest unknown)
Ipsilateral RT criteria:
Tumor within the tonsillar
fossa or ≥ 1 cm from
midline
Staging imaging:
Information not available

Median follow-up: 5.3 y
CNF rates: 0/58
N0: 0/25
N1: 0/14
N2a: 0/10
N2b: 0/4
N3: 0/5
5-y LC rates:
91%
5-y RC rates:
87%

2

(Continues)
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TABLE 1

(Continued)
Contralateral neck failure
(CNF) and salvage therapy

Level of
evidence

Median follow-up: 7.1 y
CNF rates: 1/76 (1.3%)
N0: 0/27
N1: 0/15
N2a: 0/8
N2b: 1/26 (37 mo post-RT)
5-y LC rates:
97%
5-y RC rates:
93%

Patient #1: initial T1N2b;
salvage ND + CRT with
cisplatin; NED

2

61 patients
Ipsilateral RT criteria:
T1-3N0-2b/3
Well-lateralized primary without
involvement of the base of the
tongue, soft or hard palate
Staging imaging:
CT and/or MRI
PET/CT in majority (51/61)
44 (72%) had tonsillectomy
and 34 patients (56%) had
ipsilateral neck dissection.
54 patients (89%) received
concurrent systemic therapy

Median follow-up: 3.1 y
CNF rates: 1/61 (1.6%)
N0: 0/0
N1: 0/15
N2a: 0/14
N2b: 1/31 (6 mo post-RT)
N3: 0/1

Patient #1: initial T2N2b,
salvage ND + RT; NED

2

Singleinstitution
case series

37 patients (23 p16+)
Ipsilateral RT criteria:
>1 cm from midline
Staging imaging:
PET/CT required

Median follow-up: 2.7 y
CNF rates: 0/37
N0: 0/4
N1: 0/9
N2a: 0/3
N2b: 1/21
3-y LRC rates:
96%

Ye et al16

Singleinstitution
case series

70 patients (53 p16+)
Ipsilateral RT criteria:
Physician discretion
Staging imaging:
CT
PET/CT (<10%)

Median follow-up: 5.7 y
CNF rates in p16+: 4/53 (7.5%)
N0: 0/15
N1: 3/18
N2a: 1/7
N2b: 0/11
N3: 0/2
CNF rates in p16−: 1/17 (6%;
no details given)
5-y LC rates in p16+:
89%
5-y RC rates in p16+:
83%

Koo and Wu17

Singleinstitution
case series

20 patients
Ipsilateral RT criteria:
T1-3N0-2b
not cross midline and <1 cm
of tumor invasion into the
soft palate or BOT
Staging imaging:
CT and/or MRI
PET/CT in 14/25
Surgery + adj RT: 14 patients
(4 received chemotherapy)

Median follow-up: 5.3 y
CNF rates: 0/20
N0: 0/2
N1: 0/8
N2a: 0/2
N2b: 0/8
5-y LC rates:
95%

Reference

Study type

Study population

Results

Kennedy
et al13

Singleinstitution
case series

76 patients (p16 missing in
88%)
Ipsilateral RT criteria:
Information not available
Staging imaging:
Information not available
32 (42 %) underwent a planned
neck dissection and 21 (28
%) patients received
concomitant chemotherapy

Dan et al14

Singleinstitution
case series

Hu et al15

3

No detail on each patient
Patient #1: also had DM;
palliative RT; DOD
Patients #2-4: salvage ND only;
one NED, one DOD, one
died from another cause

2

3
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TABLE 1
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(Continued)
Contralateral neck failure
(CNF) and salvage therapy

Level of
evidence

Median follow up: 2.8 y
CNF rates: 1/34
N1: 1/6
N2a: 0/8
N2b: 0/19
N2: 0/1
5-y LC rates:
95%

Patient #1: pT2cN1 initially;
postop PET/CT showed a
borderline contralateral
level 2 node with SUV of
3.3. Patient underwent
ipsilateral IMRT to 70 Gy in
35 fractions. CNF at 1-y
post-RT in the prior
suspicious lymph node.
Received salvage ND alone.
NED for 7 y

3

53 patients (49 p16+)
Ipsilateral RT criteria:
T1-2N0-2b
Not extending to ≤1 cm from
midline; not invading the
BOT, posterior pharyngeal
wall or >1/3 of the soft
palate
Staging imaging:
CT and/or MRI
PET/CT in challenging cases

Median follow up: 5.7 y
CNF rates: 4/53 (7.5%)
N0: 0/10
N1: 0/10
N2a: 0/5
N2b: 4/28

All 4 patients had p16+ T1N2b
tumors. 3 had 3 or more
multi-level nodes
Patient #1: recurred 18 mo
after RT; salvage ND + CRT;
DOD
Patient #2: recurred 43 mo after
RT; salvage ND + CRT; NED
Patient #3: recurred 23 mo after
RT; salvage ND + CRT; DOD
Patient #4: recurred 34 mo after
RT; definitive CRT; NED

2

Reference

Study type

Study population

Results

Gottumukkala
et al18

Singleinstitution
case series

34 patients (25 p16+; 1 p16−;
rest unknown)
Ipsilateral RT criteria:
T1-4N0-2b/3
Disease confined to tonsillar
fossa or ≤1/3 of the soft
palate
Staging imaging:
CT and/or MRI
PET/CT in 14/25
16 (47%) had transoral resection
before radiation and 10 (29%)
of them also underwent neck
dissections. All received
definitive or adjuvant
radiation to the primary site
and ipsilateral neck

Maskell et al19

Singleinstitution
case series

Postoperative radiation
Chin et al20

Singleinstitution
case series

154 patients treated with
postoperative IMRT
107 with lateralized primary
and cN0-2b disease:
Group 1: 48 received unilateral
IMRT
Group 2: 59 received bilateral
IMRT
47 patients had nonlateralized
primary or N2c to N3
disease and received
bilateral IMRT (group 3)

5-y LC rates:
Group 1: 100%
Group 2: 96%
Group 3: 94%
(no difference)
5-y OS rates:
Group 1: 85%
Group 2: 79%
Group 3: 76%
(no difference)
No contralateral neck
recurrences among
unilaterally treated patients

2

Rackley et al21

Singleinstitution
case series

81 patients (51 p16+) with
lateralized tonsil SCC
(cT1-2, cN0-2b per AJCC
seventh) treated with
surgery and unilateral
adjuvant (chemo)
radiotherapy
N0 = 18 patients (22%)
N1 = 3 patients (4%)
N2a = 12 patients (15%)
N2b = 48 patients (59%)

Of 67 patients who underwent
neck dissection:
18 (27%) extranodal extension
(ENE)
30 (45%) had ≥3 involved
lymph nodes
29 (43%) had a node ≥30 mm
5-y LC rates: 95%
5-y PFS rates: 93%
5-y OS rates: 91%
No contralateral failure after a
median follow-up of 5.7 y

2

(Continues)
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TABLE 1

(Continued)

Reference

Study type

Study population

Results

Kim et al22

Multiinstitution
case series

241 patients
cT1-2 and cN0-2b tonsil SCC
from 16 institutions
All had tonsillectomy (no neck
dissection) and postop RT
84 ipsilateral
157 bilateral
70 patients were identified
from each group by
propensity score matching

Ipsi vs Bilateral RT–
5-y DMFS rates: 93% vs 97%
(P = .08)
5-y LRRFS rates: 88% vs 97%
(P = .37)
5-y DFS rates: 81% vs 94%
(P = .08)
5-y OS rates: 93% vs 94%
(P = .99)
No contralateral neck
recurrence in 61 patients
with T1-2N0-2a regardless of
the treatment groups
For 79 patients with N2b,
contralateral neck
recurrence was more
common in the ipsi RT
group than in the bilateral
RT group (7.9% vs 0.0%), but
the difference was not
significant (P = .107)

Contralateral neck failure
(CNF) and salvage therapy

Level of
evidence
2

Note: Level of evidence key: (1) The conclusions of the study are valid and strongly supported by study design, analysis and results. (2) The
conclusions of the study are likely valid, but study design does not permit certainty. (3) The conclusions of the study may be valid but the evidence supporting the conclusions is inconclusive or equivocal. (4) The conclusions of the study may not be valid because the evidence may
not be reliable given the study design or analysis.
Abbreviations: BOT, base of tongue; CNF, contralateral neck failure; CRT, chemoradiation; CT, computed tomography; DFS, disease-free survival;
DM, distant metastasis; DMFS, distant metastasis-free survival; DOD, dead of disease; IMRT, intensity-modulated radiotherapy; LC, local control;
LRRFS, locoregional recurrence-free survival; MRI, magnetic resonance imaging; ND, neck dissection; NED, no evidence of disease; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; RC, regional control; RT, radiation therapy; SUV, standard uptake value.

not found in the literature search. Of the 49 citations,
30 citations were retained for further detailed review, and
14 of them were added to the evidence table. Articles
were removed from the bibliography if they were not relevant or generalizable to the topic, focused on unknown
primary disease, or were not otherwise deemed relevant
for any form of citation in the revised narrative text.

discussion. We then calculated the median score and
determined the level of agreement based on the BIOMED
Concerted Action on Appropriateness definition.7 The
strength of recommendations was graded using the
GRADE system.8

3 | RESULTS
2.2 | Consensus voting
The lead author and panelists created and reviewed several clinical variants with corresponding treatment
options representing commonly encountered clinical scenarios. Panelists anonymously rated each treatment using
a score of “1 to 9,” representing “usually not appropriate”
(1-3), “may be appropriate” (4-6), and “usually appropriate” (7-9). The results were reviewed and disagreements
discussed, then a second round of voting was performed
and results were finalized after another round of

3.1 | Topic 1: Updated literature on
clinically staged tonsil cancer (variant 1)
Review and interpretation of the literature cited in the
initial 2012 publication will not be repeated in this
update. Studies published since 2012 are summarized in
Table 1. The widespread adoption of pretreatment Positron Emission Tomography - Computed Tomography
(PET/CT) imaging has improved clinical detection of
occult nodal metastases and potentially made physicians
less concerned about otherwise occult adenopathy in the

TSAI ET AL.

contralateral side of the neck. The recently published
prospective ACRIN 6685 trial specifically affirmed the
satisfactory negative predictive value of PET/CT imaging
for cN0 neck among 212 head and neck squamous carcinoma cancer patients (with 270 cN0 necks) undergoing
planned neck dissection, with a negative predictive value
of 0.94 when using a variety of standardized uptake value
maximum (SUVmax) cutoff values.23 Many of the cited
studies here employed PET/CT staging for guiding clinical decision making, unlike those in the 2012
publication.
The largest case series of ipsilateral radiation therapy
(RT) for tonsil SCC describes 185 patients with welllateralized oropharyngeal tumors. Seventy percent of the
patients had tumor confined to the tonsillar fossa, 25%
had cancer of the soft palate (at least 1 cm away from the
midline), and 5% had cancer of the lateral pharyngeal
wall.9 Most patients had cN0 neck disease (50%),
although a small proportion (17%) had multiple ipsilateral nodes. With a median follow-up of 4.1 years,
2 patients (1.1%) developed contralateral nodal failure.
Both patients were successfully salvaged with surgery
and postoperative RT resulting in an ultimate regional
control rate of 100%.
Similar findings were observed in a previously cited
series where 102 patients were treated with ipsilateral
neck radiation. Both primary and nodal disease factors
were taken into consideration and ipsilateral RT was
delivered to patients with well-lateralized T1 to T2 tonsillar primaries limited to the lateral one-third of the base
of tongue or soft palate (≤1 cm of superficial mucosa of
“hemistructure” extension, without muscle involvement
or any suspicion of deeper penetration). Most patients
were either cN0 (54%) or had a single ipsilateral node not
larger than 3 cm (26%), or larger than 3 cm (11%). Very
few had multiple ipsilateral nodes (n = 8, 8%).11 This represents a limited sampling (25%) of patients with tonsil
cancer seen at their institution. Those who received ipsilateral RT had a 5-year contralateral recurrence rate of 2%
(2% for p16+ and 3% for p16−) with no distant progression, both occurring in patients with T2 disease and a single node no larger than 3 cm.11 There was no association
between contralateral disease development and p16 status.
A study of 37 patients (65% were p16+) with more generous, prospectively defined criteria for unilateral therapy
(oropharyngeal cancers >1 cm away from midline
irrespective of T- or N-category designation) demonstrated
no contralateral progression during a median follow-up of
32 months. In this series, 4/37 patients had T3 disease and
21/37 (62%) had multiple involved ipsilateral nodes ≤6 cm
in diameter. The 3-year locoregional control, contralateral
neck progression, distant metastasis, and disease-free survival rates were 96%, 0%, 7%, and 93%, respectively.15

7

Several other retrospective series reported low rates of
contralateral nodal failure in select patients. In a series of
76 patients who received unilateral RT, with a median
follow-up of 7.1 years, there was a single contralateral
neck recurrence in level III for a patient with cT1 tonsil
cancer and multiple ipsilateral nodes ≤6 cm. This
occurred 37 months after completion of treatment and
the patient was successfully salvaged with neck dissection followed by adjuvant RT and concurrent cisplatin.
In this series, 34% of the patients had multiple ipsilateral
nodes ≤6 cm in size, 42% underwent a planned ipsilateral
neck dissection, and 28% also received concurrent chemotherapy.13 In another series of 58 patients treated with
unilateral RT, in which 33% had multiple ipsilateral
nodes or nodes >3 cm in size, no contralateral nodal
failure was noted even in those with advanced nodal
category.12 A smaller study of 20 patients with welllateralized tonsil SCC and <1 cm invasion into the soft
palate or base of tongue (BOT) patients (1 with T3, and 8
with multiple involved nodes ≤6 cm) also found no contralateral failure at a median follow up of 64 months.17 In
another series of 61 patients with well-lateralized cancer
without any involvement of BOT or soft palate, with a
median follow-up of 37.2 months, only 1 contralateral
nodal failure was seen. The authors reported a 5-year
overall survival of 94% and disease-free survival of 86%.14
The highest contralateral recurrence rates were
reported in a recent single institution study of
53 patients in Norfolk, UK.19 The authors reviewed
133 patients with tonsil SCC treated with definitive 3Dconformal RT from 2004 to 2011, including 53 (40%)
patients receiving ipsilateral neck RT.19 The majority
of the patients had p16-positive disease (92.5%), and
half of the patients had multiple nodes ≤6 cm (52.8%).
During a median follow-up of 68 months, four (7.5%)
patients developed contralateral nodal recurrence; all
four had p16-positive T1 primaries with multiple nodes
≤6 cm at initial diagnosis. Two patients had successful
salvage. The other two patients died from their disease;
one succumbed to metastatic cancer, and the other
developed progressive regional recurrence after salvage
neck dissection and CRT, dying from the disease. All
contralateral neck recurrences occurred among
patients with multiple ipsilateral nodes ≤6 cm. In all,
14% (4/28) of patients with this node designation had
contralateral nodal recurrences. However, the small
sample size limited further evaluation of the significance of nodal burden or extent of spread across multiple nodal levels in this cohort.
Additional studies including patients with somewhat
more advanced T- and N-categories (see Table 1) have
been reported. Medial extension appears to be an important determinant for appropriately selecting patients for

8

ipsilateral neck radiation in the published reports with
low contralateral nodal failure rates; primary tumors
need to be at least 1 cm from midline at the most medial
extent12,15 or involve <1 cm of involvement of base of
tongue and/or soft palate.13,14,17
Although the data are limited, the published experiences demonstrate low rates of contralateral failure in
both p16-positive and p16-negative subsets, suggesting
that a separate selection algorithm based on p16 status is
not warranted. No other biologic or molecular criteria
have been validated as predisposing for a risk of greater
contralateral nodal spread. Therefore, the committee
does not recommend distinguishing eligibility for ipsilateral radiation based on p16 status.
One should regard these reported series as composed
of highly selected patients; even the patients with
advanced primary or nodal disease were likely those
judged to be the most favorable candidates based on the
overall sense of their clinical team.
Based on the criteria that have been established and
used to select patients for unilateral therapy, and similar
to the recommendation that was issued in the earlier
guideline, the committee maintains that unilateral therapy should be reserved for patients with tumors that are
tonsil-confined or either >1 cm from midline or involve
≤1 cm of the mucosa of the base of tongue and/or soft
palate (including the glossotonsillar sulcus). The committee did not reach a consensus on the appropriate use of
bilateral neck irradiation in cases of multiple ipsilateral
nodes, lymph nodes with clinical extranodal extension
(ENE), or a single large (>6 cm) ipsilateral lymph node.
There are insufficient data to comment on the relationship between clinical/radiographical/pathological ENE
and contralateral failure.

3.2 | Topic 2: Updated literature on
pathologically staged tonsil cancer
(variant 2)
The initial 2012 analysis reviewed three publications of
primary tonsil cancer managed with bilateral neck dissections. The current manuscript includes three additional publications (Table 1) and an additional
surgical-only series (not included in Table 1) specifically evaluating bilateral neck dissections for tonsil
cancer.24 This analysis included relatively few patients
but revealed that 4/14 (29%) of patients treated with a
bilateral neck dissection had occult disease in the contralateral side of the neck. The only predictive factor
suggestive of occult contralateral disease on the multivariable analysis was multilevel involvement of the
ipsilateral neck.

TSAI ET AL.

Similar to the management principles commonly
employed for patients treated with primary RT, most
patients managed with primary surgery who have medial
extension of the primary tumor (to within 1 cm of the
midline) are either managed with bilateral neck dissections or elective radiation given postoperatively to the
contralateral side of the neck. Similar to reports of
patients treated with primary radiation, there have been
surgically oriented publications evaluating the outcomes
of patients who initially present with >1 node and/or
ENE who are managed with unilateral therapy.

3.2.1 | Subtopic 1: Patients with multiple
pathologic nodes
One series examined 107 patients with lateralized tonsil
cancers and cN0 to single or multiple involved nodes
≤6 cm who underwent surgery followed by unilateral or
bilateral IMRT. Beginning in 2007, patients with tonsil
cancer >1 cm from midline were routinely treated unilaterally regardless of pathologic findings from the neck.
Consequently, 48 patients received unilateral IMRT and
59 received bilateral IMRT.20 Of patients in the unilateral
RT group, 23 (48%) had 2 to 5 positive nodes, 5 (10%) had
>5 positive nodes, and 77% had pathologic ENE. These
numbers were comparable to the bilateral RT group. The
5-year locoregional control rates and survival were
similar between the two groups of patients (5-year localregional control of 100% for unilateral and 96% for bilateral treatments). With a median follow-up of 5.5 years,
no contralateral neck recurrences developed among
patients treated unilaterally. Unilateral IMRT reduced
acute toxicity and improved patient-reported quality of
life compared with bilateral IMRT.20
Another report reviewed 81 patients (n = 51, p16 positive) with lateralized tonsil SCC (cT1-2, cN0 to single or
multiple ipsilateral nodes ≤ 6 cm) treated with surgery
(9 simple tonsillectomies without further surgery to the
oropharynx, 64 transoral laser microsurgery, and 8 cases
lip split mandibulotomy with a free tissue/pedicle flap)
and unilateral adjuvant radiotherapy. Of 67 patients, who
underwent neck dissection, 30 (45%) had three or more
involved lymph nodes, 29 (43%) had a node ≥3 cm, and
18 (27%) had ENE. With a median follow-up of 5.7 years,
there were no contralateral recurrences reported. Fiveyear overall survival, progression-free survival, and
locoregional control were 91.0%, 93.0%, and 95.4%,
respectively.21
In a propensity-score matched, pooled analysis of
241 patients from 16 institutions who underwent various
forms of tonsillectomy (without neck dissection) from
2001 to 2012 followed by adjuvant radiation, 70 selected
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patients who received ipsilateral adjuvant radiation were
matched to another 70 patients with bilateral adjuvant
radiation.22 Of note, the authors did not specifically state
if the surgical procedure was simple tonsillectomy or
oncologic radical tonsillectomy. The two groups of
patients had similar survival outcomes. There was no
contralateral neck recurrence in 61 patients with pathologic T1-2 and clinical N0 to a single node ≤6 cm. Among
79 patients with clinical multiple nodes ≤6 cm,
38 received ipsilateral RT and 41 bilateral
RT. Contralateral neck recurrence was 3/38 (7.9%) in
ipsilateral RT group vs 0 in bilateral RT group (P = .107).
Notably, two of the three patients with contralateral neck
failures also experienced local recurrence. With a median
follow-up of 55 months, a total of 11 patients (15.7%) with
pathologic T1 to T2, clinical N0 disease in the ipsilateral
RT group experienced local recurrence, whereas only
three patients (4.3%) developed recurrence in the bilateral
RT group; this was primarily attributable to a high rate of
local failure and not to a single isolated contralateral
neck failure. It is unclear if the recurrence was related to
treatment with less than radical tonsillectomy.
Another study of 34 patients with well-lateralized,
node-positive tonsillar SCC treated with either definitive
or adjuvant radiation to the primary site and ipsilateral
side of the neck showed only one (3%) contralateral failure during a median follow-up of 34 months.18 Of the
34 patients, 16 (47%) had transoral resection before radiation and 10 (29%) of them also underwent neck dissections. All patients received definitive or adjuvant
radiation to the primary site and ipsilateral neck. The
5-year local control rate was 95%.
The highest rate of contralateral failure after adjuvant
unilateral RT for lateralized tonsil cancer was described
in a series of 136 patients (57% of whom underwent an
ipsilateral neck dissection pre-radiotherapy) treated with
unilateral RT. Although the contralateral node recurrences were infrequent and a univariate/multivariate
analysis was not performed, the authors comment that
among the 8 patients with contralateral progression,
6 had multiple positive ipsilateral nodes, most had pathologic ENE, and most had >10 pack years smoking. However, the number of cases used to reach these conclusions
was small and only 8/136 (5.9%) patients in this series
had experienced a contralateral recurrence, at a median
follow-up of 4.2 years.10
Surgical considerations for tonsil cancer may differ
from those regarding definitive ipsilateral RT. In addition
to oncologic factors, functional outcomes, anatomic considerations, and comorbidity are important aspects for
determining a proper surgical candidate.25 In many
instances, the definitions of “well-lateralized” tonsil cancer from a surgeon's perspective could be different from
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that of a radiation oncologist. Hence, the appropriateness
of postoperative ipsilateral neck RT in T1 to T2 tonsil
SCC still warrants further evaluation.
We strongly recommend that a multidisciplinary
review and discussion of these cases be performed prior
to initiation of therapy. Proper communication is crucial
in selecting the initial treatment modality and in optimal
management of the contralateral neck.

3.3 | Topic 3: Role of chemotherapy
At present, there is limited evidence supporting the
hypothesis that chemotherapy alone eradicates potential
microscopic disease outside the radiation treatment fields.
Furthermore, it is unclear what doses of radiation are
needed with or without concurrent chemotherapy to successfully eradicate microscopic disease in the ipsilateral or
contralateral neck for either p16-positive or p16-negative
oropharyngeal carcinoma. Therefore, with the paucity of
evidence, the committee does not take a position on the
usefulness of planned concurrent chemotherapy in determining a patient's eligibility for ipsilateral RT.

3.4 | Topic 4: Salvage of contralateral
progression in the unirradiated
contralateral neck
The retrospective reports cited in this guideline all demonstrated low rates of contralateral recurrence. Collectively, there are a total of 26 cases of contralateral disease
progression. Of these, 19 cases were successfully treated
and reported as controlled at time of publication. Thus,
73% cases with contralateral progression were reported as
successfully managed with a variety of treatment regimens and <1% (7 of 1031) of patients managed unilaterally experienced contralateral progression that was not
successfully treated. These results are similar to a prior
review of 1116 patients with mean contralateral neck failure rate of 2.42% and salvage rate of 73%.26

3.5 | Topic 5: Proton therapy
The search did not return any literature specifically
addressing ipsilateral radiation for tonsil cancer using
proton therapy. A published retrospective ipsilateral proton therapy series combined multiple histologic entities
and subsites of head and neck cancer.27 Prospective studies on proton therapy for ipsilateral treatment of tonsil/
oropharyngeal cancer are underway (NCT01893307,
NCT03829033).
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4 | S UM MA R Y O F
RECOMMENDATIONS
• Definitive (chemo)radiotherapy:
 The committee strongly recommends that the use of
ipsilateral radiation is usually appropriate for a
tonsil-confined tumor with a minimal burden of
nodal disease such as 0 to 2 involved lymph nodes
discussed in variant 1. However, there were differing
perspectives on the precise number and size of clinically involved nodes that constitute a “minimal burden of disease.” There was agreement that
unilateral therapy is usually appropriate for a tonsillar fossa-based tumor with ≤1 cm of tumor invasion
into the soft palate or base of tongue (variant 1). The
committee acknowledges the importance of the clinical exam and variation in individual anatomy when
quantifying the amount of soft palate and base of
tongue involvement.
 The committee does not recommend ipsilateral therapy for patients with >1 cm of tumor extension into
the mucosa of the base of tongue and/or soft palate.
Instead, the committee strongly recommends bilateral neck irradiation in these cases, deemed as usually appropriate due to the increased risk of occult
contralateral nodal spread (variant 3).
 The committee strongly recommends the use of
bilateral neck irradiation as usually appropriate in
cases with tumor extension to the posterior pharyngeal wall and in the presence of ipsilateral retropharyngeal lymphadenopathy (variants 4 and 6).
However, the committee did not reach a consensus
regarding the appropriate use of ipsilateral neck
irradiation for a tonsil-confined tumor with a single
ipsilateral retropharyngeal node (variant 6).
 The committee did not reach a consensus on the
appropriate use of bilateral neck irradiation in cases
of multiple ipsilateral nodes, lymph nodes with clinical ENE or a single large (>6 cm) ipsilateral lymph
node (variants 1, 2, and 5).
 The panel does not recommend consideration of
HPV status or the use of concurrent chemotherapy
in determining a patient's eligibility for ipsilateral
neck irradiation.
• Adjuvant (chemo)radiotherapy:
 The committee recommends the use of ipsilateral
neck irradiation as usually appropriate after resection of a well-lateralized tonsil primary tumor
with a single ipsilateral pathologically positive node,
regardless of microscopic ENE in the node or perineural invasion and lymphovascular space invasion
in the primary specimen (variants 7 and 10). The
committee did not reach a consensus on the
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appropriate use of bilateral neck irradiation for
these pathologic features.
 The committee strongly recommends the use of
bilateral neck irradiation as usually appropriate
after neck dissection in cases of multiple pathologically positive ipsilateral lymph nodes and in the
presence of macroscopic extranodal extension (variants 8 and 9). The committee did not reach a consensus on the appropriate use of ipsilateral neck
irradiation in this setting.
 The committee did not reach a consensus on the
appropriate use of ipsilateral or bilateral neck irradiation in patients with a close (<1 mm) mucosal
margin at the base of tongue (variant 11).
• Committee note: For many of the case variants, the
committee did not reach agreement, likely due to a
lack of level 1 evidence supporting specific treatment
decisions. This indicates an unmet need for higherquality research specifying the exact criteria for unilateral radiation in future prospective clinical trials
(Data S1).
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A P P END I X : CASE VARIANTS
Clinical condition: Primary radiation-based therapy
Variant 1: Patient with primary tumor 2 cm, confined to the tonsillar fossa, one 3-cm mobile ipsilateral node in level
2, and one mobile 1-cm ipsilateral node in level 3.
Issues raised: What is the maximum number of nodes for which unilateral therapy is appropriate?

Treatment

Rating category

Group median rating

Ipsilateral RT

A

7

Bilateral RT

M

5

Disagree
×

Reference

SOE

SOR

13-15,19,20,24-26

S

"

13-15,19,20,24-26

M

-

Variant 2: Patient with primary tumor 1.8 cm confined to the tonsillar fossa, single 4-cm lymph node on exam growing
through skin.
Issues raised: Does clinical ENE trigger a recommendation of bilateral therapy in a well-lateralized tumor?
Treatment

Rating category

Group median rating

Disagree

Reference

SOE

SOR

Ipsilateral RT

M

6

×

-

L

-

Bilateral RT

M

7

×

-

L

-

Variant 3: Patient with primary tumor 2.5 cm, invading 1.5 cm into the soft palate and/or tongue base, no lymph nodes
bilaterally.
Issues raised: Does proximity to midline trigger bilateral therapy when the ipsilateral neck is cN0?
Treatment

Rating category

Group median rating

SOE

SOR

Ipsilateral RT

U

2

Disagree

12,13,16-19,24-25

Reference

S

"

Bilateral RT

A

8

12,13,16-19,24,25

S

"

Variant 4: Patient with primary tumor 2.5 cm, invading posterior pharyngeal wall, no lymph node bilaterally.
Issues raised: Does involvement of posterior pharyngeal wall trigger a recommendation of bilateral therapy when the ipsilateral neck is cN0?
Treatment

Rating category

Group median rating

Reference

SOE

SOR

Ipsilateral RT

U

3

Disagree

-

-

"

Bilateral RT

A

8

-

-

"

Variant 5: Patient with primary tumor 1.5 cm, confined to the tonsillar fossa, single 7-cm mobile ipsilateral node.
Issues raised: What is the largest single node for which unilateral therapy is appropriate?

Treatment

Rating category

Group median rating

Disagree

Reference

SOE

SOR

Ipsilateral RT

M

4

×

-

-

-

Bilateral RT

M

7

×

-

-

-
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Variant 6: Patient with primary tumor 2 cm, confined to the tonsillar fossa, single ipsilateral 1.5 cm lateral retropharyngeal node seen on cross-sectional imaging.
Issues raised: Does involvement of a retropharyngeal node trigger a recommendation for bilateral therapy?
Treatment

Rating category

Group median rating

Disagree

Reference

SOE

SOR

Ipsilateral RT

M

3

×

-

-

-

Bilateral RT

A

8

-

-

"

Clinical condition: Adjuvant radiation-based therapy
Variant 7: Patient with resected primary tumor confined to tonsillar fossa and single ipsilateral node with ENEmi
(ENE 1 mm).
Issues raised: Does microscopic ENE in an otherwise well lateralized tumor impact the decision of unilateral therapy?

Treatment

Rating category

Group median rating

Ipsilateral RT

A

7

Bilateral RT

M

5

Disagree
×

Reference

SOE

SOR

-

-

"

-

-

-

Variant 8: Patient with resected primary tumor with 0.5 cm soft palate and/or tongue base invasion, five ipsilateral
nodes, no ENE.
Issues raised: Does number of positive nodes pathologically impact the decision of unilateral therapy?
Treatment

Rating category

Group median rating

Disagree

Reference

SOE

SOR

Ipsilateral RT

M

5

×

21-23

L

-

Bilateral RT

A

8

21-23

M

"

Variant 9: Patient with significant medical comorbidity with resected primary tumor with <1 cm of soft palate/BOT
involved, two ipsilateral nodes, + ENEma (5 mm of ENE).
Issues raised: Does major ENE in a lateralized tumor trigger a recommendation of bilateral therapy? Do age/comorbidities
of the patient matter?
Treatment

Rating category

Group median rating

Disagree

Reference

SOE

SOR

Ipsilateral RT

M

6

×

22

L

-

Bilateral RT

A

7

22

L

"

Variant 10: Patient with resected primary tumor with <1 cm of soft palate/BOT involved, PNI and LVSI on specimen,
single 2-cm ipsilateral lymph node with no ENE.
Issues raised: Do PNI and LVI influence a recommendation of bilateral neck therapy?
Treatment

Rating category

Group median rating

Ipsilateral RT

A

7

Bilateral RT

M

4

Disagree
×

Reference

SOE

SOR

-

-

"

-

-

-
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Variant 11: Patient with T1N1 tonsil cancer with <0.5 cm BOT invasion clinically. Underwent radical tonsillectomy +
limited tongue base resection and ipsilateral neck dissection and final pathology reveals 2.2-cm primary tumor with
<1 mm margin on BOT and single 1.5-cm ipsilateral lymph node with no ENE.
Issues raised: Should we irradiate the contralateral neck based on the close margin?
Treatment

Rating category

Group median rating

Disagree

Reference

SOE

SOR

Ipsilateral RT

M

6

×

21,22

L

-

Bilateral RT

M

6

×

21,22

L

-

Abbreviations: EC, expert consensus; EO, expert opinion; L, limited; M, moderate; RT, radiation therapy; S, strong;
SOE, strength of evidence; SOR, strength of recommendation; ", strong recommendation; #, weak recommendation;
-, not strong, not weak.
Note: Refer to the supporting documentation for a more complete discussion of the concepts and their definitions
below. Rating categories: A, usually appropriate; M, may be appropriate; U, usually not appropriate. Disagreement: The
variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation
(see the narrative text). Group median rating is set automatically to 5. References show the lists of the references associated with the recommendation.

